KINIKSA PHARMACEUTICALS LTD's ticker is KNSA and the CUSIP is G5269C101. A total of 133 filers reported holding KINIKSA PHARMACEUTICALS LTD in Q1 2023. The put-call ratio across all filers is 0.58 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $2,270,103 | +23.4% | 130,691 | 0.0% | 1.01% | +21.6% |
Q2 2023 | $1,840,129 | +50.6% | 130,691 | +15.1% | 0.83% | +65.4% |
Q1 2023 | $1,221,690 | -66.9% | 113,540 | -67.2% | 0.50% | -4.2% |
Q4 2022 | $3,689,000 | -28.2% | 346,500 | -27.8% | 0.52% | -53.7% |
Q3 2022 | $5,140,000 | 0.0% | 480,000 | 0.0% | 1.13% | +93.7% |
Q2 2022 | $5,140,000 | +7.7% | 480,000 | 0.0% | 0.58% | -47.2% |
Q1 2022 | $4,771,000 | +637.4% | 480,000 | +772.7% | 1.11% | +539.9% |
Q4 2021 | $647,000 | -88.5% | 55,000 | -88.9% | 0.17% | -83.6% |
Q3 2021 | $5,646,000 | -18.2% | 495,748 | 0.0% | 1.06% | -11.3% |
Q2 2021 | $6,905,000 | -24.7% | 495,748 | 0.0% | 1.19% | -28.5% |
Q1 2021 | $9,176,000 | +4.8% | 495,748 | 0.0% | 1.67% | -1.1% |
Q4 2020 | $8,759,000 | +15.3% | 495,748 | 0.0% | 1.69% | +1.3% |
Q3 2020 | $7,594,000 | -39.9% | 495,748 | 0.0% | 1.67% | -45.6% |
Q2 2020 | $12,631,000 | +64.6% | 495,748 | 0.0% | 3.06% | +51.3% |
Q1 2020 | $7,674,000 | – | 495,748 | – | 2.02% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Fairmount Funds Management LLC | 2,474,561 | $42,983,125 | 5.17% |
Rubric Capital Management LP | 3,077,449 | $53,455,289 | 2.00% |
Parkman Healthcare Partners LLC | 509,810 | $8,855,400 | 1.62% |
TANG CAPITAL MANAGEMENT LLC | 600,000 | $10,422,000 | 1.47% |
AlphaCentric Advisors LLC | 110,000 | $1,910,700 | 1.08% |
Lion Point Capital, LP | 130,691 | $2,270,103 | 1.01% |
RICE HALL JAMES & ASSOCIATES, LLC | 650,366 | $11,296,857 | 0.72% |
ESSEX INVESTMENT MANAGEMENT CO LLC | 185,853 | $3,228,267 | 0.53% |
ADVISORY RESEARCH INC | 204,098 | $3,545,182 | 0.49% |
Jackson Creek Investment Advisors LLC | 65,607 | $1,140 | 0.48% |